Competitive Advantages
- Could be an effective treatment for Alzheimer
- Might be able to fix neuronal damage and promote neuron growth
- Minimal toxicity thus would minimize the side effects
Summary
Effective therapies and/or cures for central nervous system (CNS) disorders like Alzheimer’s which impose a tremendous socioeconomic burden are currently lacking.
The invention describes the development of a new peptidomimetics. Sulfono-γ-AA peptides take advantage of immense chemical diversity and has been tested for anti-amyloid aggregation activity and neuronal toxicity. In vitro studies with primary neurons demonstrated a peptide named 125-6b was non-toxic and prompted neuronal growth. In vivo studies with the App/ps1 mouse model of AD showed that 125-6b can inhibit/reduce amyloid beta aggregation and prevent memory impairment. Flow cytometry data from the in vivo experiments indicated that the compound has no significant impact to the immune system of the recipient subject, so it is safe from immunological perception.
Left: Treatment of murine primary neurons with 125-6b is well tolerated and can increase neuron viability.
Right: Administration of 125-6b in the App/ps1 mouse model of AD improves working memory in animals (assessed by examining number of errors and latency in a 2-block and 3-block radial arm water maze (RAWM) behavioral test).
Desired Partnerships
- License
- Sponsored Research
- Co-Development